NovoCure Ltd (NVCR) Actualités

Novocure gibt positive Ergebnisse der Phase-3-Studie PANOVA-3 zur Tumor Treating Fields (TTFields)-Therapie bei Bauchspeicheldrüsenkrebs bekannt

PANOVA-3 erreichte den primären Endpunkt mit einer statistisch signifikanten Verbesserung des Gesamtüberlebens bei Patienten mit...

ノボキュア、膵がんに対する腫瘍治療電場療法（TTフィールド）の第3相臨床試験PANOVA-3のトップライン結果を発表

PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に...

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally...

Form 8-K - Current report

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally...

Novocure to Participate in Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference...

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the...

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Novocure présente ses résultats financiers pour le troisième trimestre 2024

Le chiffre d’affaires net trimestriel s’est élevé à 155 millions USD, en hausse de 22 % en glissement annuel, avec un nombre record de 4 113...